Unicycive Therapeutics Inc.
13F holders, Q4 2024 (December 31)31holders +2
7new positions
6sold out
$0.79avg. 13F price*
At the end of Q4 2024, 31 institutions reported holding Unicycive Therapeutics Inc. in their 13F filings, up 2 from Q3 2024. 7 opened new positions and 6 sold out. The largest holders were Great Point Partners LLC ($8.7M), Nantahala Capital Management, LLC ($8.3M) and Octagon Capital Advisors LP ($7.9M).
- Company
- Unicycive Therapeutics Inc.
- CUSIP
- 90466Y103
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $42K |
| Exits | 6 | $287K |
All 13F filers, Q3 2024 → Q4 2024: 17,662,652 shares bought and 2,748,304 shares sold, net +14,914,348 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 31 holders
| Great Point Partners LLC | 4.11% | Add +28.3% | 10,980,000 | $8.7M |
| Nantahala Capital Management, LLC | 0.58% | Add +268.5% | 10,391,994 | $8.3M |
| Octagon Capital Advisors LP | 1.35% | Add +16.8% | 10,000,000 | $7.9M |
| Vivo Capital, LLC | 0.89% | Add +123.0% | 9,970,152 | $7.9M |
| Logos Global Management LP | 0.47% | No change | 5,078,927 | $4.0M |
| Walleye Capital LLC | 0.04% | No change | 5,000,000 | $4.0M |
| Silverarc Capital Management, LLC | 0.44% | Reduce -37.8% | 2,486,709 | $2.0M |
| Acuta Capital Partners, LLC | 1.84% | Add +16.4% | 2,303,000 | $1.8M |
| Alyeska Investment Group, L.P. | 0.01% | Reduce -22.2% | 1,750,000 | $1.4M |
| Altium Capital Management LLC | 0.36% | No change | 1,473,000 | $1.2M |
| Vanguard Group Inc. | 0.00% | No change | 1,138,220 | $904K |
| Geode Capital Management, LLC | 0.00% | Add +30.3% | 524,487 | $417K |
| XTX Topco Ltd | 0.01% | Add +142.2% | 171,463 | $136K |
| State Street Corp. | 0.00% | Add +185.0% | 125,236 | $99K |
| Goldman Sachs Group Inc. | 0.00% | Reduce -21.2% | 73,608 | $58K |
| BlackRock, Inc. | 0.00% | Add +0.6% | 72,272 | $57K |
| Northern Trust Corp. | 0.00% | Add +142.4% | 58,181 | $46K |
| Creative Planning | 0.00% | Add +121.6% | 22,674 | $18K |
| HRT Financial LP | 0.00% | New | 22,131 | $17K |
| Tandem Capital Management Corp. | 0.01% | No change | 15,500 | $12K |
| Hunter Associates Investment Management LLC | 0.00% | New | 15,000 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -52.2% | 10,888 | $9K |
| FWG Investments, LLC. | 0.01% | New | 10,218 | $8K |
| Morgan Stanley | 0.00% | New | 5,000 | $4K |
| SOA Wealth Advisors, LLC. | 0.00% | New | 1,000 | $794 |
| Citigroup Inc. | 0.00% | New | 587 | $466 |
| Bank of America Corp. | 0.00% | Add +22.3% | 406 | $322 |
| JPMorgan Chase & Co. | 0.00% | Reduce -3.9% | 199 | $158 |
| Bogart Wealth, LLC | 0.00% | New | 60 | $48 |
| SBI Securities Co., Ltd. | 0.00% | — | 49 | $39 |
| UBS Group AG | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is UNICYCIVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Unicycive Therapeutics Inc. the manager owns.